HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Silvia Comis Selected Research

danusertib

10/2011Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.
11/2009A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Silvia Comis Research Topics

Disease

2Neoplasms (Cancer)
10/2011 - 11/2009
1Rare Diseases (Rare Disease)
11/2014
1Tuberous Sclerosis (Bourneville's Disease)
11/2014
1Inborn Genetic Diseases (Disease, Hereditary)
11/2014
1Neutropenia
10/2011
1Febrile Neutropenia
11/2009
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
11/2009

Drug/Important Bio-Agent (IBA)

2danusertibIBA
10/2011 - 11/2009
1trans-sodium crocetinate (crocetin)IBA
11/2014
1Aurora Kinase AIBA
10/2011
1dimethylaniline monooxygenase (N-oxide forming) (flavin-containing monooxygenase)IBA
10/2011
1Pharmaceutical PreparationsIBA
10/2011
1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
11/2009
1Aurora KinasesIBA
11/2009